Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:ATCCode |
gptkb:C07AB03
|
| gptkbp:bioavailability |
50%
|
| gptkbp:CASNumber |
gptkb:29122-68-7
|
| gptkbp:drug_type |
approved
|
| gptkbp:drugClass |
beta blocker
|
| gptkbp:hasInChIKey |
METKIMKYRPQLGS-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C14H22N2O3
|
| gptkbp:hasSMILES |
CC(C)NCC(CO)Oc1ccc(cc1)CC(=O)N
|
| https://www.w3.org/2000/01/rdf-schema#label |
ChEMBL1226
|
| gptkbp:indication |
myocardial infarction
hypertension angina pectoris |
| gptkbp:IUPACName |
4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenylacetamide
|
| gptkbp:mechanismOfAction |
beta-1 adrenergic receptor antagonist
|
| gptkbp:molecularWeight |
266.34
|
| gptkbp:name |
gptkb:Atenolol
|
| gptkbp:PubChem_CID |
2162
DB00335 CHEBI:2904 CHEMBL1226 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:Atenololum
gptkb:Tenormin |
| gptkbp:target |
beta-1 adrenergic receptor
|
| gptkbp:UNII |
50VV3VW0TI
|
| gptkbp:bfsParent |
gptkb:Linalool
|
| gptkbp:bfsLayer |
7
|